Nucor Corporation vs Tempus AI — how do they compare? Nucor Corporation trades at $248 (market cap $55.91B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Nucor Corporation is far larger — about 4.4× Tempus AI's market cap, and Nucor Corporation pays a 0.91% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Tempus AI for 22 Days on average.
| NUE | TEM | |
|---|---|---|
Market Cap | $55.91B | $12.77B |
Volume | 1,062,743 | 8,980,490 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $274.74 | $99.28 |
52-Week Low | $131.78 | $41.55 |
Typical Hold Time | 78 Days | 22 Days |
Enterprise Value | $60.32B | $13.40B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.14, down 1.96% on the day, amid a neutral technical signal with mixed moving averages and oscillators. Recent earnings show Q1 and Q2 2026 beats, but Q3 guidance of $5.75 EPS is pending. Revenue for 2025 was $32.49B with a net income margin of 7.99%, while 2026 projections indicate a rebound to $36.1B revenue and 7.98% margin. The company maintains a strong balance sheet with $4.14B cash and a debt-to-asset ratio of 20.23% for 2025.
Outlook remains cautiously optimistic with a consensus price target of $266.88, implying ~8% upside, supported by 57.58% analyst buy ratings. Risks include competitive pressures from a new $15B Iowa steel mill and volatile steel prices, but Nucor's low-cost operations and dividend consistency (214th consecutive payout) provide stability. Investors should monitor Q3 earnings for confirmation of growth trajectory amid sector headwinds.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →